Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PPM1B | O75688 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14376239 | 1.00 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL31629067 | 1.00 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL14258637 | 1.00 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL17950624 | 0.98 | — | — | |
| SCHEMBL15563732 | 0.98 | — | — | |
| SCHEMBL12526037 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL13718632 | 0.95 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL13718634 | 0.95 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL17062447 | 0.95 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL31061871 | 0.92 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692949-A1 | POSITIVELY CHARGEABLE TONER FOR ELECTROSTATIC CHARGE IMAGE DEVELOPMENT, TONER SET, AND IMAGE FORMING METHOD | Zeon Corporation (JP) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024202238-A1 | POSITIVELY CHARGEABLE TONER FOR ELECTROSTATIC CHARGE IMAGE DEVELOPMENT, TONER SET, AND IMAGE FORMING METHOD | 日本ゼオン株式会社 | 2024-10-03 | — | — | WO | disclosed |
| US-20080058336-A1 | Methods to Treat Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2008-03-06 | — | — | US | disclosed |
| US-7276484-B2 | Dipeptide inhibitors of β-secretase | ELAN PHARMACEUTICALS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20050182138-A1 | Dipeptide inhibitors of beta-secretase | ELAN PHARMACEUTICALS, INC. | 2005-08-18 | — | — | US | disclosed |
| US-6864240-B1 | Dipeptide inhibitors of β-secretase | ELAN PHARMACEUTICALS, INC. (US) | 2005-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058336-A1 | Methods to Treat Alzheimer's Disease | PSEN2, PSEN1, ACHE | CHRNB2 16/4885CHRNA4 27/4885CHRNB4 28/4885 |
| US-20050182138-A1 | Dipeptide inhibitors of beta-secretase | BACE1, APP, BACE2 | CHRNB2 423/4885CHRNA4 1092/4885CHRNB4 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.